Table 34Summary of included studies. Comparison 33. Switching to bupropion versus switching to another antidepressant from same class

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Rush 2006

RCT

US

N=477

Mean age (years): 42.3

Gender (% female): 56

Ethnicity (% BME): 23

Baseline severity: QIDS 13.3 (more severe)

Bupropion sustained release 150-400mg/daySertraline 50-200mg/dayInadequate response (not achieved remission or who were intolerant [56%]) to an initial prospective treatment with citalopram

Treatment length (weeks): ≤14

Outcomes:

  • Depression symptomatology change score
  • Remission
  • Response
  • Discontinuation due to side effects

BME: black and minority ethnic; QIDS: quick inventory of depressive symptomatology; RCT: randomised controlled trial

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.